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A rapid rise in the incidence of oesophageal adenocarcinoma in
western societies (Devesa et al, 1998; Hansson et al, 1993) has
coincided with an increase in the prevalence of asthma (Sears,
1997). Some common asthma medications, including theo-
phylline and β agonists, relax the lower oesophageal sphincter
and facilitate gastro-oesophageal reflux, one of the strongest
known risk factors for oesophageal adenocarcinoma (Chow et al,
1995; Farrow et al, 2000; Lagergren et al, 1999a). Indeed, use
of these drugs is associated with an up to three-fold increased
risk of oesophageal adenocarcinoma (Lagergren et al, 2000a;
Vaughan et al, 1998). The fact that asthmatic patients have a
higher prevalence of gastro-oesophageal reflux than the general
population (Sontag et al, 1990, 1992) raises the question whether
the risk of oesophageal adenocarcinoma is such as to warrant
special clinical attention or screening. Further, the more common
gastric cardia cancers are also associated with gastro-
oesophageal reflux, albeit more weakly (Lagergren et al, 1999a),
but previous studies failed to find a link with asthma medications
(Lagergren et al, 2000a; Vaughan et al, 1998). Thus, the relation-
ship between asthma and cardia cancer remains an open ques-
tion. We therefore conducted a large retrospective cohort study to
quantify the risk of oesophageal and gastric cardia adenocarci-
noma, and as a comparison, the risk of oesophageal squamous-
cell carcinoma and distal stomach cancer, in adult asthmatic
patients, using data from several nationwide registers in Sweden. 
METHODS 
Study cohort 
We used the Swedish Inpatient Register, founded in 1964–65 by
the National Board of Health and Welfare, to create a cohort of
adult asthmatic patients. Each record in this register corresponds to
one in-hospital episode and contains, in addition to a unique
national registration number assigned to each Swedish resident,
administrative and medical data such as hospital department,
surgical codes, and up to six discharge diagnoses. During our
study period, the diagnoses were coded according to the seventh
revision of the International Classification of Diseases (ICD-7)
through 1968, the eighth revision until 1987 (ICD-8), and the ninth
revision thereafter (ICD-9). The number of hospitals delivering
data to the register has increased steadily: the register covered
60% of the Swedish population in 1969, 75% in 1978, and 85% by
the end of 1983 (Nyren et al, 1995). From 1987, the register
attained complete nationwide coverage. We identified a total of
118, 106 unique national registration numbers that were registered
at least once with a discharge diagnosis of asthma (ICD-7 =
241.00, 241.01; ICD-8 = 493.00, 493.09; ICD-9 = 493A, 493B,
493X) at age 20 or older between 1965 and 1994. 
Follow-up 
Record linkage of the study cohort to the nationwide Register of
Causes of Death allowed us to identify the date of death among
those deceased through 1995. Corresponding linkage to the
Emigration Register identified dates of emigration. The National
Swedish Cancer Register, founded in 1958 and close to 98%
complete (Mattsson et al, 1985), was used to ascertain all incident
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Cancer Register coded malignant neoplasms according to the ICD-
7 classification during the entire period of study. Through addi-
tional linkage to the Total Population Register, we excluded 4243
records, because their national registration numbers could not be
found in any of the aforementioned registers and were deemed
incorrect numbers. Since only first primary cancers were eligible
for study, we also excluded 8157 patients with prevalent cancers at
the time of entry. We further excluded 3017 patients who died
during the index hospitalization and 161 patients with inconsisten-
cies uncovered during record linkages. To minimize the impact of
possible selection bias, we excluded the first year of observation
after the index hospitalization, including 9542 patients who
reached any end-point (see below) during the first year. Such bias
arises if asthmatic patients with a yet undiagnosed cancer are more
likely to be hospitalized than asthmatic patients without a sub-
clinical cancer. These ‘missed’ cases are most likely to become
diagnosed during the first year of follow-up. Finally, a total of
92 986 patients, 42 663 men and 50 323 women, remained for
further analysis. 
Statistical analysis 
Follow-up began from the second year following discharge after
the first recorded (index) hospitalization for asthma, until the
occurrence of the first cancer diagnosis, emigration, death, or the
end of the observation period (December 31, 1995), whichever
came first. Since a separate code for gastric cancer in the cardia
was introduced first in 1969, cases and person-years in the
stomach cancer analyses were accumulated from 1970, 1 year
after the coding change to ensure better data quality. To avoid
possible ascertainment bias associated with differential autopsy
rates between asthmatic patients and the general population, we
excluded cancers found incidentally at autopsy. Relative risk of
cancer in the cohort was estimated as the standardized incidence
ratio (SIR), i.e., the ratio of the observed number of cancers to
that expected. The expected number of cancers were calculated
by multiplying the number of person-years observed in age-
(in 5-year groups), gender-, and calendar year strata in the cohort
by stratum-specific cancer incidence rates for the entire Swedish
population excluding cancers found incidentally at autopsy. The
95% confidence interval (CI) of the SIR was calculated by the
exact method on the assumption that the observed number of
cases follows a Poisson distribution (Breslow and Day, 1987). 
We did not have clinical data about severity, duration of asthma
before the first hospitalization, or treatment. However, we were able
to identify co-existing diseases, namely chronic bronchitis/emphy-
sema and gastro-oesophageal reflux diseases (oesophagitis, hiatal
hernia, and heart-burn symptoms), diagnosed before/at entry or
during follow-up, and use these variables as indicators for severity
of asthma or exposure to other risk factors. Stratified analyses were
performed on presence or absence of co-existing disease, allocating
person-years before the onset of co-existing diseases to the comor-
bidity-negative strata. We also stratified the analyses by selected
cohort characteristics that may influence the results, including age
or calendar period at cohort entry, and follow-up duration. 
RESULTS 
Some details of the study cohort are listed in Table 1. On average,
asthmatic patients were followed up for 8.5 years, resulting in a
total of 698 688 (622 483 for stomach cancer analysis) observed
person-years. About 4 percent of asthmatic patients had ever 
been hospitalized for gastro-oesophageal reflux diseases before 
or during follow-up. The corresponding figure for chronic bron-
chitis/emphysema was 21.7%. During the period 1–30 years
following the initial hospitalization for asthma, we observed 17
cases of oesophageal adenocarcinoma (mean age at diagnosis,
68.6 years) and 43 cases of cardia cancer (mean age at 
diagnosis, 71.4 years). 
Oesophageal cancer 
Compared with the age- and gender-matched general population,
there was a 50% excess risk for oesophageal adenocarcinoma (SIR
= 1.5, 95% CI 0.9–2.5) (Table 2). Stratified analysis by gender
revealed a higher relative risk among men than among women,
though the difference was not statistically significant. When subdi-
vided by follow-up duration, a decreased relative risk was found in
the first 4 years of follow-up. A more than 2-fold risk was detected
for those followed-up 5 years or more (SIR = 2.4, 95% CI 1.4–4.0).
Asthmatic patients who had ever been hospitalized for gastro-
oesophageal reflux diseases had a higher point estimate (SIR = 7.5,
95% CI 0.7–22.0), while only a non-significant 30% excess of rela-
tive risk was observed in the patients without documented gastro-
oesophageal reflux diseases (P value for difference between two
SIRs < 0.01). Patients recorded with co-existing chronic bron-
chitis/emphysema had a higher relative risk than those without,
although the difference was not significant (Table 2). The relative
risk tended to increase with increasing calendar year of entry into
the cohort, or with decreasing age at entry, although none of these
trends was statistically significant (data not shown). 
No significant excess risk was detected for squamous-cell carci-
noma among asthmatic patients (Table 2). The pattern of risk did
not differ materially by follow-up duration, with the relative risk
below unity after 10 years of follow-up (SIR = 0.8, 95% CI
0.3–1.4). The risks also did not differ noticeably whether or not a
concomitant condition was present (Table 2). In addition, the risk
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Table 1 Characteristics of the cohort of adult asthmatic patients, 1965–94,
Sweden 
Characteristic 
Number of patients 92 986 
Distribution by gender (%) 
Male 42 663 (45.9) 
Female 50 323 (54.1) 
Distribution by age at entry, year (%) 
20–49 25 814 (27.8) 
50–59 16 174 (17.4) 
60–69 22 483 (24.2) 
70 + 28 515 (30.7) 
Average age at entry, years 59.1 
Distribution by calendar year at entry (%) 
65–74 16 036 (17.2) 
75–84 31 225 (33.6) 
85–94 45 725 (49.2) 
Average calendar year at entry 1983 
Distribution by duration of follow-up, years (%) 
1–4 35 703 (38.4) 
5–9 26 503 (28.5) 
10 + 30 780 (33.1) pattern did not change substantially across age or calendar period
at cohort entry (data not shown). 
Stomach cancer 
A marginally significant 40% excess risk of gastric cardia cancer
was observed (SIR = 1.4, 95% CI 1.0–1.9) in asthmatic patients,
with no consistent change with follow-up duration (Table 3). The
relative risk was higher among women than among men, though
the difference was not statistically significant. Stratification
according to comorbidity showed relative risks close to unity in
those without recorded co-existing diseases (Table 3). The excess
risk increased with increasing calendar year of entry into the
cohort, or with decreasing age at cohort entry, although none of
these trends was statistically significant (data not shown). 
There was no increased risk for cancer of the distal stomach.
In fact, a significant reduction in risk was observed after 10 or
more years of follow-up. No obvious difference was noted by
comorbidity status (Table 3). 
DISCUSSION 
We found a 50% increased relative risk for oesophageal adenocar-
cinoma among asthmatic patients, consistent with the hypothe-
sized link via gastro-oesophageal reflux. Also observed was a
marginally significant 40% excess risk of gastric cardia cancer.
There was no excess risk of oesophageal squamous-cell carcinoma
or stomach cancer distal to the gastric cardia. 
Gastro-oesophageal reflux has been associated with substantial
increase in risk of oesophageal adenocarcinoma (Chow et al, 1995;
Farrow et al, 2000; Lagergren et al, 1999a). The prevalence of
gastro-oesophageal reflux symptoms is reportedly higher in asth-
matic patients than in subjects without asthma (Sontag et al, 1990,
1992), though some may have clinically silent reflux (Irwin et al,
Gastro-oesophageal cancers in asthmatic patients 1319
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Table 2 Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for cancers of the oesophagus among adult asthmatic
patients, 1965–94, Sweden 
Adenocarcinoma of the oesophagus Squamous-cell carcinoma of the oesophagus  
Characteristic Obs* SIR 95% CI Obs* SIR 95% CI 
Total 17 1.5 0.9–2.5 46 1.1 0.8–1.4 
Gender 
Male 15 1.7 1.0–2.8 37 1.3 0.9–1.7 
Female 2 0.9 0.1–3.1 9 0.7 0.3–1.3 
Follow-up, year 
1–4 1 0.2 0.01–1.3 19 1.1 0.6–1.7 
5–9 8 2.4 1.0–4.7 18 1.4 0.8–2.2 
≥ 10 8 2.5 1.1–4.9 9 0.8 0.3–1.4 
Gastro-oesophageal reflux diseases†
No 14 1.3 0.7–2.2 45 1.1 0.8–1.5 
Yes 3 7.5 1.6–22.0 1 0.7 0.02–3.9 
Chronic bronchitis or emphysema† 
No 10 1.2 0.6–2.2 35 1.1 0.7–1.5 
Yes 7 2.7 1.1–5.6 11 1.2 0.6–2.1 
*Observed number of cancer cases. 
†Person-years before the onset of co-existing diseases were allocated to the comorbidity-negative stratum. 
Table 3 Standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for cancers of the stomach among adult asthmatic
patients, 1970–94, Sweden 
Cancer of the gastric cardia Cancer of the stomach other than cardia  
Characteristic Obs* SIR 95% CI Obs* SIR 95% CI 
Total 43 1.4 1.0–1.9 219 0.9 0.8–1.1 
Gender 
Male 28 1.2 0.8–1.8 136 0.9 0.8–1.1 
Female 15 2.0 1.1–3.3 83 0.9 0.7–1.1 
Follow-up, year 
1–4 13 1.0 0.5–1.7 113 1.0 0.8–1.2 
5–9 19 2.0 1.2–3.1 73 1.0 0.8–1.2 
≥ 10 11 1.4 0.7–2.5 33 0.6 0.4–0.9 
Gastro-oesophageal reflux diseases†
No 35 1.2 0.8–1.7 214 0.9 0.8–1.1 
Yes 8 7.1 3.1–14.0 5 0.6 0.2–1.5 
Chronic bronchitis or emphysema†
No 27 1.2 0.8–1.7 148 0.8 0.7–0.9 
Yes 16 2.2 1.3–3.6 71 1.3 1.0–1.7 
*Observed number of cancer cases. 
†Person-years before the onset of co-existing diseases were allocated to the comorbidity-negative stratum. 1993). These observations are supported by clinical evidence among
asthmatic patients indicating a high prevalence of oesophagitis
(Sontag et al, 1992), decreased oesophageal sphincter pressure
(Kjellen et al, 1981; Sontag et al, 1990), and increased acid contact
time measured through ambulatory 24-hour oesophageal pH moni-
toring (Harding et al, 1999; Vincent et al, 1997). Nevertheless, the
relationship between gastro-oesophageal reflux and asthma is not
well understood. While gastro-oesophageal reflux may be a trigger
for asthma and medical or surgical treatment of reflux can improve
asthma outcomes (Field et al, 1999; Field and Sutherland, 1998),
medications for asthma can cause or worsen gastro-oesophageal
reflux. Recent epidemiological studies have linked asthma medica-
tions, including theophylline and β -agonists, to an increased risk of
oesophageal adenocarcinoma (Lagergren et al, 2000a; Vaughan et
al, 1998). However, in epidemiological studies based on self-
reported medication and medical histories it is difficult to separate
the effects of asthma drugs from those of possible underlying reflux
associated with asthma. Nevertheless, our results suggest that the
absolute risk of oesophageal adenocarcinoma among asthma
patients is small. 
Gastro-oesophageal reflux is associated with a moderately
increased risk of gastric cardia adenocarcinoma (Chow et al, 1995;
Lagergren et al, 1999a), but of the two studies of the association
between asthma drug treatment and gastro-oesophageal adenocar-
cinoma risk, neither found any excess risk of cardia cancer associ-
ated with such medication (Lagergren et al, 2000a; Vaughan et al,
1998). We observed an elevated relative risk for gastric cardia
cancer among asthmatic patients, of similar magnitude to that for
oesophageal adenocarcinoma. Smoking, a risk factor for these
cancers (Gammon et al, 1997; Lagergren et al, 2000b) and an
aggravating factor of adult asthma (Floreani and Rennard, 1999),
may not be an explanation, since we did not observe any excess of
oesophageal squamous-cell carcinoma, which is more strongly
linked to smoking (Gammon et al, 1997; Lagergren et al, 2000b).
Obesity is another possible confounder (Camargo et al, 1999;
Chow et al, 1998; Lagergren et al, 1999b). Unfortunately, the
restrictive use of the obesity diagnosis in overweight patients
hospitalized for other reasons than their weight problem prevented
us from effectively controlling for this condition. 
To the best of our knowledge, this is the first cohort study to
examine the risk of adenocarcinomas of the oesophagus and
gastric cardia in subjects with asthma. The design of the present
study has the strength of reducing potential recall and selection
biases. Further, the high quality of Swedish national registers
ensures near-complete follow-up, and high accuracy of our
outcome information with 90–100% of the oesophageal cancers
being histologically confirmed (Centre for epidemiology, the
National Board of Health and Welfare, 1975, 1985, 1995).
However, some limitations should also be noted. First, data on
asthma severity, duration before index hospitalization or treatment
is lacking. Asthma is a common disease, and those who were
hospitalized are likely to have had more severe forms or more co-
existing diseases. Thus, our estimates may not be representative of
asthma as a whole and, if severity increases cancer risk, we may
have overestimated the risk of gastro-oesophageal adenocarci-
nomas. On the other hand, we used the general population as
reference, in which around 5% have asthma (Lundback et al, 1993;
Montnemery et al, 1998), which would lead to some underestima-
tion of the true association. Finally, despite the relatively large
cohort size, the number of cancer cases was small, yielding limited
statistical power for detailed analysis. 
In conclusion, asthmatic patients are at moderately elevated risk
of developing oesophageal or gastric cardia adenocarcinoma. The
most plausible mechanism is via gastro-oesophageal reflux. The
absolute excess risk for these two types of adenocarcinomas was
small so that management changes seem unjustified. However, the
possibility of oesophageal and gastric cardia adenocarcinoma
development in asthmatic patients with clinically manifest gastro-
oesophageal reflux should be kept in mind. 
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